50 results
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
2 Feb 24
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
7:46am
million primarily due to the reacquired mavacamten rights of $445 million in China and certain other Asian territories. On a GAAP and non-GAAP basis
8-K
EX-99.1
89xl8htfc6r
26 Oct 23
Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
7:44am
8-K/A
EX-99.1
50lfcx
5 Feb 20
Report of Independent Registered Public Accounting Firm
4:42pm
8-K
EX-99.1
10uwnqggskb9yi
8 Mar 19
Report of Independent Registered Public Accounting Firm
7:02am
425
EX-99.1
i7cckbm
8 Mar 19
Business combination disclosure
7:00am
425
476j7s ts
19 Feb 19
Business combination disclosure
5:21pm
8-K
EX-99.1
fbdl4prr42 ufnoa
19 Dec 18
Bristol-Myers Squibb Announces Offer from
4:19pm